A metabolomic investigation of serum perfluorooctane sulfonate and perfluorooctanoate.

[1]  D. Silverman,et al.  A prospective nested case-control study of serum concentrations of per- and polyfluoroalkyl substances and aggressive prostate cancer risk. , 2023, Environmental research.

[2]  D. Conti,et al.  Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort , 2022, JHEP reports : innovation in hepatology.

[3]  Andrew J. Shapiro,et al.  Systematic Evidence Map for Over One Hundred and Fifty Per- and Polyfluoroalkyl Substances (PFAS) , 2022, Environmental health perspectives.

[4]  Caroline H. Johnson,et al.  Non-targeted metabolomics and associations with per- and polyfluoroalkyl substances (PFAS) exposure in humans: A scoping review. , 2022, Environment international.

[5]  Karilyn E. Sant,et al.  Associations between Exposures to Perfluoroalkyl Substances and Diabetes, Hyperglycemia, or Insulin Resistance: A Scoping Review , 2021, Journal of xenobiotics.

[6]  Dean P. Jones,et al.  Exposure to Perfluoroalkyl Substances and Glucose Homeostasis in Youth , 2021, Environmental health perspectives.

[7]  M. Petriello,et al.  Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury. , 2021, Environment international.

[8]  K. Kleinman,et al.  Temporal trends of concentrations of per- and polyfluoroalkyl substances among adults with overweight and obesity in the United States: Results from the Diabetes Prevention Program and NHANES. , 2021, Environment international.

[9]  M. Maceyka,et al.  Sphingolipids in metabolic disease: The good, the bad, and the unknown. , 2021, Cell metabolism.

[10]  Song Tang,et al.  Exposure to legacy and novel perfluoroalkyl substance disturbs the metabolic homeostasis in pregnant women and fetuses: A metabolome-wide association study. , 2021, Environment International.

[11]  B. Le Bizec,et al.  Non-targeted screening methodology to characterise human internal chemical exposure: Application to halogenated compounds in human milk. , 2021, Talanta.

[12]  I. Johansson,et al.  Plasma metabolites associated with exposure to perfluoroalkyl substances and risk of type 2 diabetes - A nested case-control study. , 2020, Environment international.

[13]  Carla A. Ng,et al.  Per‐ and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research , 2020, Environmental toxicology and chemistry.

[14]  M. McCullough,et al.  Identification and Reproducibility of Plasma Metabolomic Biomarkers of Habitual Food Intake in a US Diet Validation Study , 2020, Metabolites.

[15]  Q. Tang,et al.  Uric acid is associated with adiposity factors, especially with fat mass reduction during weight loss in obese children and adolescents , 2020, Nutrition & Metabolism.

[16]  D. Silverman,et al.  Serum concentrations of per- and polyfluoroalkyl substances and risk of renal cell carcinoma. , 2020, Journal of the National Cancer Institute.

[17]  L. Balluz,et al.  Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014. , 2020, Chemosphere.

[18]  A. Braeuning,et al.  Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells , 2020, Archives of Toxicology.

[19]  D. Albanes,et al.  Associations between metabolites and pancreatic cancer risk in a large prospective epidemiological study , 2020, Gut.

[20]  M. Bloom,et al.  Isomers of per- and polyfluoroalkyl substances and uric acid in adults: Isomers of C8 Health Project in China. , 2019, Environment international.

[21]  M. Orešič,et al.  Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography–tandem mass spectrometry , 2019, Analytical and Bioanalytical Chemistry.

[22]  Yawei Wang,et al.  Mass Spectrometry-Based Metabolomics Reveals Occupational Exposure to Per- and Polyfluoroalkyl Substances Relates to Oxidative Stress, Fatty Acid β-Oxidation Disorder, and Kidney Injury in a Manufactory in China. , 2019, Environmental science & technology.

[23]  A. Castaño,et al.  Associations of multiple exposures to persistent toxic substances with the risk of hyperuricemia and subclinical uric acid levels in BIOAMBIENT.ES study. , 2019, Environment international.

[24]  A. Calafat,et al.  Per- and polyfluoroalkyl substances and fluorinated alternatives in urine and serum by on-line solid phase extraction-liquid chromatography-tandem mass spectrometry. , 2018, Chemosphere.

[25]  E. Ingelsson,et al.  Identification of metabolic profiles associated with human exposure to perfluoroalkyl substances , 2018, Journal of Exposure Science & Environmental Epidemiology.

[26]  M. McCullough,et al.  Untargeted Metabolomics Identifies Novel Potential Biomarkers of Habitual Food Intake in a Cross-Sectional Study of Postmenopausal Women. , 2018, The Journal of nutrition.

[27]  R. Hoover,et al.  A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk , 2018, Journal of the National Cancer Institute.

[28]  M. Laville,et al.  Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients? , 2018, Toxins.

[29]  Y. Li,et al.  Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water , 2017, Occupational and Environmental Medicine.

[30]  K. Kleinman,et al.  Plasma Concentrations of Per- and Polyfluoroalkyl Substances at Baseline and Associations with Glycemic Indicators and Diabetes Incidence among High-Risk Adults in the Diabetes Prevention Program Trial , 2017, Environmental health perspectives.

[31]  Heqing Shen,et al.  Serum metabolome biomarkers associate low-level environmental perfluorinated compound exposure with oxidative /nitrosative stress in humans. , 2017, Environmental pollution.

[32]  S. Sang,et al.  Urinary Biomarkers of Whole Grain Wheat Intake Identified by Non-targeted and Targeted Metabolomics Approaches , 2016, Scientific Reports.

[33]  C. Lu,et al.  The identification of the metabolites of chlorothalonil in zebrafish (Danio rerio) and their embryo toxicity and endocrine effects at environmentally relevant levels. , 2016, Environmental pollution.

[34]  D. Albanes,et al.  Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial , 2016, British Journal of Cancer.

[35]  Christian Gieger,et al.  A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. , 2016, Journal of the American Society of Nephrology : JASN.

[36]  Sonia Borodzicz,et al.  Sphingolipids in cardiovascular diseases and metabolic disorders , 2015, Lipids in Health and Disease.

[37]  J. Odland,et al.  Maternal serum concentrations of per- and polyfluoroalkyl substances and their predictors in years with reduced production and use. , 2014, Environment international.

[38]  A. Calafat,et al.  Changes in Serum Concentrations of Maternal Poly- and Perfluoroalkyl Substances over the Course of Pregnancy and Predictors of Exposure in a Multiethnic Cohort of Cincinnati, Ohio Pregnant Women during 2003–2006 , 2014, Environmental science & technology.

[39]  John P A Ioannidis,et al.  Design and analysis of metabolomics studies in epidemiologic research: a primer on -omic technologies. , 2014, American journal of epidemiology.

[40]  Joshua N Sampson,et al.  Metabolomics in nutritional epidemiology: identifying metabolites associated with diet and quantifying their potential to uncover diet-disease relations in populations. , 2014, The American journal of clinical nutrition.

[41]  C. Dalgård,et al.  Adiposity and glycemic control in children exposed to perfluorinated compounds. , 2014, The Journal of clinical endocrinology and metabolism.

[42]  L. Jeng,et al.  Urinary Nucleosides as Biomarkers of Breast, Colon, Lung, and Gastric Cancer in Taiwanese , 2013, PloS one.

[43]  P. Edwards,et al.  Pleiotropic roles of bile acids in metabolism. , 2013, Cell metabolism.

[44]  M. Longnecker,et al.  Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women. , 2013, Environment international.

[45]  S. Stringer,et al.  Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury , 2013, Front. Physiol..

[46]  C. Gieger,et al.  Serum metabolite concentrations and decreased GFR in the general population. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  M. DeLorenzo,et al.  Comparative risk assessment of permethrin, chlorothalonil, and diuron to coastal aquatic species. , 2012, Marine pollution bulletin.

[48]  A. Shankar,et al.  Perfluoroalkyl chemicals and elevated serum uric acid in US adults , 2011, Clinical epidemiology.

[49]  Kyle Steenland,et al.  Association of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) with Uric Acid among Adults with Elevated Community Exposure to PFOA , 2009, Environmental health perspectives.

[50]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[51]  Yu-Chuan Lin,et al.  Association Among Serum Perfluoroalkyl Chemicals, Glucose Homeostasis, and Metabolic Syndrome in Adolescents and Adults , 2008, Diabetes Care.

[52]  A. Calafat,et al.  Polyfluoroalkyl Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and Comparisons with NHANES 1999–2000 , 2007, Environmental health perspectives.

[53]  D. Galaris,et al.  Uric acid and oxidative stress. , 2005, Current pharmaceutical design.

[54]  A. Seifalian,et al.  The contemporary role of antioxidant therapy in attenuating liver ischemia‐reperfusion injury: A review , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[55]  D. Deutschman,et al.  Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. , 2003, American heart journal.

[56]  Raymond Vanholder,et al.  Review on uremic toxins: classification, concentration, and interindividual variability. , 2003, Kidney international.

[57]  Ronald J A Wanders,et al.  A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency. , 2002, Biochimica et biophysica acta.

[58]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[59]  D. Spiegelman,et al.  Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. , 1999, American journal of epidemiology.

[60]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[61]  Chien-Yu Lin,et al.  Association among total serum isomers of perfluorinated chemicals, glucose homeostasis, lipid profiles, serum protein and metabolic syndrome in adults: NHANES, 2013-2014. , 2018, Environmental pollution.

[62]  J. Gleason,et al.  Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007-2010. , 2015, Environmental research.

[63]  F. Nieto,et al.  Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? , 2000, Atherosclerosis.

[64]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..